Tessel and Sanofi Collaborate on AI for Target Discovery

We’re excited to announce we’re collaborating with Sanofi to accelerate AI for target discovery!

The best models of biology are the hardest ones to scale. Clinical predictive power comes at the cost of the throughput (and data quantity) that cutting-edge AI so badly needs.

At Tessel, we’re building a unique tech stack that respects the reality of scarce data in biology. A key part of this is Tesselogic, our active learning platform. Using Tesselogic, we have already uncovered promising drug targets for lung disease and beyond. We prioritize generating the most informative training data when experiments are rate limiting.

Now, we’re coupling this data with the right architecture to predict clinically-correlated outcomes.

We’re training a modular foundation model to predict how the collective function of cells in a tissue emerges from their internal molecular machinery. When combined with our active learning platform, this new kind of virtual tissue will potentially enable us to find better drug targets, faster than ever before.

We’re thrilled to be working on this project with Sanofi – an industry leader who shares our commitment to both I&I and AI.

– Naren